Unknown

Dataset Information

0

B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.


ABSTRACT: The pathogenesis of nephrotic syndrome is unclear. However, the efficacy of rituximab, a B cell-depleting antibody, in nephrotic syndrome suggests a pathogenic role of B cells. In this retrospective study, we determined by flow cytometry levels of B and T cell subpopulations before and after rituximab infusion in 28 pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome. At baseline, patients had lower median percentages of transitional and mature B cells than age-matched healthy controls (P<0.001). Rituximab induced full depletion of B cells (<1% of lymphocytes). At 1 year, most patients exhibited complete total and mature B cell recovery, whereas memory B cell subsets remained significantly depleted. Total T cell concentration did not change with rituximab, whereas the CD4(+)/CD8(+) T cell ratio tended to increase. Fourteen patients relapsed within 24 months, with a median follow-up of 11.2 months (interquartile range, 8-17.7 months). We observed no difference at baseline between nonrelapsing and relapsing patients in several clinical parameters and cell subset concentrations. Reconstitution of all memory B cell subpopulations, number of immunosuppressive drugs, and dose of tacrolimus during the last 4 months of follow-up were predictive of relapse in univariate Cox regression analysis. However, only delayed reconstitution of switched memory B cells, independent of immunosuppressive treatment, was protective against relapse in multivariate (P<0.01) and receiver operator characteristic (P<0.01 for percentage of lymphocytes; P=0.02 for absolute count) analyses. Evaluation of switched memory B cell recovery after rituximab may be useful for predicting relapse in patients with nephrotic syndrome.

SUBMITTER: Colucci M 

PROVIDER: S-EPMC4884116 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.

Colucci Manuela M   Carsetti Rita R   Cascioli Simona S   Casiraghi Federica F   Perna Annalisa A   Ravà Lucilla L   Ruggiero Barbara B   Emma Francesco F   Vivarelli Marina M  

Journal of the American Society of Nephrology : JASN 20151113 6


The pathogenesis of nephrotic syndrome is unclear. However, the efficacy of rituximab, a B cell-depleting antibody, in nephrotic syndrome suggests a pathogenic role of B cells. In this retrospective study, we determined by flow cytometry levels of B and T cell subpopulations before and after rituximab infusion in 28 pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome. At baseline, patients had lower median percentages of transitional and mature B cells than age-m  ...[more]

Similar Datasets

| S-EPMC3358759 | biostudies-literature
| S-EPMC3968490 | biostudies-literature
| S-EPMC3816123 | biostudies-literature
| S-EPMC4577716 | biostudies-literature
| S-EPMC6524616 | biostudies-literature
| S-EPMC9727513 | biostudies-literature
| S-EPMC4876225 | biostudies-literature
| S-EPMC3162962 | biostudies-literature
| S-EPMC6061657 | biostudies-literature
| S-EPMC6646679 | biostudies-literature